XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
XORTX (NASDAQ: XRTX) received a Nasdaq notice on October 20, 2025 that it is not in compliance with the minimum $1.00 bid price requirement under Nasdaq Rule 5550(a)(2) after the closing bid fell below $1.00 for 30 consecutive business days.
The company has a 180-calendar-day cure period from the notification date to regain compliance while the shares continue to trade on the Nasdaq Capital Market. Regaining compliance requires the bid price to close at or above $1.00 for a minimum of 10 consecutive business days (subject to Nasdaq discretion). XORTX said it will evaluate options to resolve the deficiency; the notice does not affect its TSX Venture Exchange listing.
XORTX (NASDAQ: XRTX) ha ricevuto un avviso da Nasdaq il 20 ottobre 2025 che non rispetta il requisito minimo di prezzo di offerta di 1,00 USD ai sensi della Regola Nasdaq 5550(a)(2) dopo che l’offerta di chiusura è scesa al di sotto di 1,00 USD per 30 giorni lavorativi consecutivi.
L’azienda dispone di un periodo di cura di 180 giorni di calendario dalla data di notifica per tornare conforme, mentre le azioni continuano a essere negoziate sul Nasdaq Capital Market. Per tornare conforme, il prezzo di offerta deve chiudere a 1,00 USD o superiore per un minimo di 10 giorni lavorativi consecutivi (soggetto alla discrezionalità di Nasdaq). XORTX ha dichiarato che valuterà opzioni per risolvere la deficienza; l’avviso non influisce sull’omologazione su TSX Venture Exchange.
XORTX (NASDAQ: XRTX) recibió un aviso de Nasdaq el 20 de octubre de 2025 que no cumple con el requisito mínimo de precio de oferta de 1,00 USD bajo la Regla 5550(a)(2) de Nasdaq, después de que la oferta de cierre cayera por debajo de 1,00 USD durante 30 días hábiles consecutivos.
La empresa tiene un periodo de curación de 180 días naturales desde la fecha de notificación para volver a cumplir, mientras las acciones continúan negociándose en Nasdaq Capital Market. Para volver a cumplir, el precio de la oferta debe quedarse cerrado en 1,00 USD o más durante un mínimo de 10 días hábiles consecutivos (sujeto a la discreción de Nasdaq). XORTX señaló que evaluará opciones para resolver la deficiencia; el aviso no afecta su cotización en TSX Venture Exchange.
XORTX (NASDAQ: XRTX) 는 2025년 10월 20일에 나스닥으로부터 최소 1.00달러의 매수가격 요건을 충족하지 못한다는 통보를 받았으며, 30영업일 연속 동안 종가가 1.00달러 아래로 떨어진 결과입니다. 나스닥 규칙 5550(a)(2)에 따른 것입니다.
통지일로부터 180일(캘린더 데이)의 시정 기간이 주어지며, 주식은 Nasdaq Capital Market에서 계속 거래됩니다. 시정 요건을 충족하려면 매수가가 1.00달러 이상으로 최소 10영업일 연속 종가를 기록해야 합니다(나스닥의 재량으 로). XORTX는 결함을 해결하기 위한 옵션을 평가할 것이라고 밝혔으며, 이 통지는 TSX Venture Exchange 상장에 영향을 주지 않습니다.
XORTX (NASDAQ : XRTX) a reçu un avis de Nasdaq le 20 octobre 2025 indiquant qu’il ne respecte pas l’exigence minimale de cours d’offre de 1,00 USD conforme à la règle Nasdaq 5550(a)(2) après que l’offre de clôture est tombée en dessous de 1,00 USD pendant 30 jours ouvrables consécutifs.
L’entreprise dispose d’une période de cure de 180 jours calendaire à partir de la date de notification pour redevenir conforme, tandis que les actions continuent d’être négociées sur le Nasdaq Capital Market. Pour retrouver la conformité, le cours d’offre doit clôturer à 1,00 USD ou plus pendant au moins 10 jours ouvrables consécutifs (sous réserve de la discrétion de Nasdaq). XORTX a déclaré qu’elle envisagerait des options pour résoudre la déficience ; l’avis n’affecte pas son inscription à la TSX Venture Exchange.
XORTX (NASDAQ: XRTX) erhielt am 20. Oktober 2025 eine Benachrichtigung von Nasdaq, dass es nicht den Mindest-Offerpreis von 1,00 USD gemäß Nasdaq-Regel 5550(a)(2) erfüllt, nachdem das Schlussangebot 30 aufeinanderfolgende Handelstage lang unter 1,00 USD gefallen war.
Das Unternehmen hat eine 180-tägige Kalendertage-Heilungsfrist ab dem Benachrichtigungsdatum, um die Konformität wiederherzustellen, während die Aktien weiter am Nasdaq Capital Market gehandelt werden. Um die Konformität wiederherzustellen, muss der Angebotspreis 1,00 USD oder mehr schließen und dies für mindestens 10 aufeinanderfolgende Handelstage tun (im Ermessen von Nasdaq). XORTX sagte, es werde Optionen prüfen, um die Unstimmigkeit zu lösen; die Mitteilung beeinträchtigt nicht die Listung an der TSX Venture Exchange.
تلقت XORTX (NASDAQ: XRTX) إخطاراً من ناسداك في 20 أكتوبر 2025 يفيد بأنها ليست ممتثلة لمتطلب الحد الأدنى لسعر العرض البالغ 1.00 دولار وفقًا للقواعد 5550(a)(2) من ناسداك، بعد أن انخفض سعر العرض الإغلاق دون 1.00 دولار لمدة 30 يوم عمل متتالية.
لدى الشركة فترة علاج مدتها 180 يومًا تقويمياً من تاريخ الإخطار لاستعادة الامتثال بينما تستمر الأسهم في التداول في Nasdaq Capital Market. لاستعادة الامتثال، يجب أن يغلق سعر العرض عند 1.00 دولار أو أكثر لمدة لا تقل عن 10 أيام عمل متتالية (وفقاً لتقدير ناسداك). قالت XORTX إنها ستقيّم خيارات لحل النقص؛ لا يؤثر الإخطار على إدراجها في TSX Venture Exchange.
XORTX（NASDAQ: XRTX） 于 2025 年 10 月 20 日 收到纳斯达克通知，表示其未能符合纳斯达克规则 5550(a)(2) 下的最低 1.00 美元出价要求，因为收盘报价在 30 个连续交易日 内跌破 1.00 美元。
自通知之日起，公司有一个 180 天日历日的 cure 期限以恢复合规，同时股票在纳斯达克资本市场继续交易。要恢复合规，出价需在至少连续 10 个交易日内收于 1.00 美元或以上（以纳斯达克的裁量为准）。XORTX 表示将评估解决缺陷的选项；该通知不影响其在 TSX Venture Exchange 的上市地位。
- Shares continue trading during the 180-calendar-day cure period
- Regain compliance by closing at ≥$1.00 for 10 consecutive business days
- Closing bid below $1.00 for 30 consecutive business days
- Has 180 calendar days (from Oct 20, 2025) to cure or face potential delisting
Insights
XORTX received Nasdaq notice for sub-$1.00 bid price and has
The company currently trades on the Nasdaq Capital Market and received notice after the closing bid remained below
The main operational channel is straightforward: restore the share price above the threshold or meet alternative listing criteria within the cure window. Risks include continued low trading price and potential future delisting if the company fails to meet the stated requirement. Track the share price over the next
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces receipt of notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares listed on Nasdaq was below US
These notifications do not impact the Company’s listing on the Nasdaq Capital Market at this time. In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification to regain compliance with the minimum bid price requirement, during which time the shares will continue to trade on the Nasdaq Capital Market. If at any time before the 180 calendar day period, the bid price of the shares closes at or above US
The Company is also listed on the TSX Venture Exchange and the notification letter does not affect the Company’s compliance status with such listing.
The Company intends to evaluate all available options to resolve the deficiency and regain compliance with Nasdaq Rule 5550(a)(2).
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.
| For more information, please contact: | |
| Allen Davidoff, CEO adavidoff@xortx.com or +1 403 455 7727 | Nick Rigopulos, Director of Communications nick@alpineequityadv.com or +1 617 901 0785 |
Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Forward Looking Statements
This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.
FAQ
What did XRTX announce on October 20, 2025 about Nasdaq compliance?
How long does XRTX have to regain Nasdaq compliance for symbol XRTX?
What specific price condition will return XRTX to compliance with Nasdaq?
Will XRTX shares stop trading on Nasdaq during the cure period?
Does the Nasdaq notice affect XRTX’s TSX Venture Exchange listing?
